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Abstract
Background: Onchocerciasis causes a considerable disease burden in Africa, mainly through skin and eye disease. Since
1995, the African Programme for Onchocerciasis Control (APOC) has coordinated annual mass treatment with ivermectin in
16 countries. In this study, we estimate the health impact of APOC and the associated costs from a program perspective up
to 2010 and provide expected trends up to 2015.
Methods and Findings: With data on pre-control prevalence of infection and population coverage of mass treatment, we
simulated trends in infection, blindness, visual impairment, and severe itch using the micro-simulation model ONCHOSIM,
and estimated disability-adjusted life years (DALYs) lost due to onchocerciasis. We assessed financial costs for APOC,
beneficiary governments, and non-governmental development organizations, excluding cost of donated drugs. We
estimated that between 1995 and 2010, mass treatment with ivermectin averted 8.2 million DALYs due to onchocerciasis in
APOC areas, at a nominal cost of about US$257 million. We expect that APOC will avert another 9.2 million DALYs between
2011 and 2015, at a nominal cost of US$221 million.
Conclusions: Our simulations suggest that APOC has had a remarkable impact on population health in Africa between 1995
and 2010. This health impact is predicted to double during the subsequent five years of the program, through to 2015.
APOC is a highly cost-effective public health program. Given the anticipated elimination of onchocerciasis from some APOC
areas, we expect even more health gains and a more favorable cost-effectiveness of mass treatment with ivermectin in the
near future.
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Onchocerciasis is caused by Onchocerca volvulus, a filarial
nematode restricted to human hosts. The adult female worms
reside in subcutaneous nodules where they produce millions of
microfilariae during their on-average ten-year life span [1]. The
microfilariae are found predominantly migrating through the skin
and eyes and are transmitted by biting flies of the genus Simulium
(the vector), an obligatory part of the parasite’s life cycle.
Onchocerciasis is responsible for a considerable burden of disease,
mainly because of visual impairment, blindness, disfiguring skin
lesions, and severe itching, which are the results of continuous
exposure to microfilariae. Most of the global burden of oncho-
cerciasis (.99%) is found in sub-Saharan Africa. In the West
African savanna, where onchocerciasis is of a severely blinding
form (savanna type), fear of blindness previously led to abandon-
ment of fertile river basins. However, by now, onchocerciasis has
been largely eliminated from West Africa by the Onchocerciasis
Control Programme (1974–2002), which relied on intense vector
control and mass treatment with the drug ivermectin [2].
In the more central and eastern parts of Africa, where
onchocerciasis is usually of the less blinding form (forest type),
there was no control or control only at a limited scale until the
inception of the African Programme for Onchocerciasis Control
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(APOC) in 1995. APOC is a morbidity control program scheduled
to be active until 2015, requiring that by that year, participating
countries support and coordinate control measures independently.
Since 1995, APOC has mapped infection with O. volvulus in 20
countries [3] and has coordinated interventions in 16 countries
where onchocerciasis is considered a public health problem
(Angola, Burundi, Cameroon, Central African Republic, Chad,
Congo, Democratic Republic of Congo, Equatorial Guinea,
Ethiopia, Liberia, Malawi, Nigeria, South Sudan, Sudan,
Tanzania, and Uganda), covering endemic areas inhabited by
about 71.5 million people in 1995. APOC’s main strategy is to
implement annual mass treatment with ivermectin.
Ivermectin kills microfilariae and permanently reduces the
production of microfilariae by adult female worms, slowing down
transmission and preventing morbidity [4,5]. Annual mass
treatment with ivermectin is implemented through a communi-
ty-directed treatment approach, empowering communities to take
responsibility for ivermectin delivery and to decide how, when,
and by whom ivermectin treatment is administered. Mass
treatment with ivermectin is enabled by donation of the drug by
the pharmaceutical company Merck through the Mectizan
Donation Program. Furthermore, coordination of the program is
funded by donor countries (through the World Bank) and national
onchocerciasis task forces (including beneficiary governments and
non-governmental development organizations). To demonstrate
APOC’s importance, validate the efforts of endemic communities
and national task forces, and maintain commitment of all
stakeholders, it is essential to establish the health impact and cost
of APOC.
Here, we present the estimated impact of APOC on population
health and the costs involved up to 2010, with extrapolated trends
up to 2015. An impact assessment would ideally be based on
observed trends of infection and morbidity, but such longitudinal
data are of limited availability in APOC areas. We therefore
estimated trends of infection and morbidity based on APOC data
of pre-control levels of infection and history of mass treatment, and
literature-derived associations between infection and morbidity
and the effect of treatment on infection and morbidity. For our
calculations, we used ONCHOSIM, an established micro-
simulation model for transmission and control of onchocerciasis
[6,7].
Methods
Project-population by endemicity category and project-
specific history of control
The impact of APOC was estimated at project level (a project
being an implementation unit for mass treatment with ivermectin),
while taking account of the prevailing type of onchocerciasis (i.e.,
savanna versus forest or mixed forest/savanna, with different
patterns of morbidity) and the project-specific history of control.
Project populations were further stratified by endemicity groups,
to take account of differences in the pre-control prevalence of
morbidity (which is non-linearly associated with infection) and the
potential impact of mass treatment (e.g., the impact is relatively
lower in highly endemic areas due to more residual transmission
between treatment rounds). We considered four endemicity levels:
non-endemic (prevalence of onchocercal nodules in adult males
,1%), hypoendemic (nodule prevalence $1% and ,20%),
mesoendemic (nodule prevalence $20% and ,40%), and
hyperendemic (nodule prevalence $40%).
We estimated the size of the population at risk for infection in
the 107 geographical project areas covered by APOC, for the
years 1995–2010 (see File S1). These estimates were based on
records kept by community-appointed drug distributors, aggre-
gated to the project level. From the same data, we took the
reported number of individuals who were treated with ivermectin
during mass treatment (File S1) and calculated the average
therapeutic coverage of mass treatment in each project per
calendar year (i.e., the fraction of the population at risk that was
treated). Based on data from extensive pre-control mapping
studies, we estimated the fraction of the population in the different
endemicity categories and the mean pre-control infection level in
each endemicity category (File S1).
For the years 2011–2015, we assumed that population size will
increase according to the latest known national growth rate (as
reported by the United Nations World Population Prospects,
published 11 May 2010, accessed 24 October 2011). If therapeutic
coverage in 2010 was already at or above 75%, we assumed that
coverage in the years 2011–2015 will remain equal to that in 2010.
For those few project in which this was not yet the case, we
assumed that between 2011 and 2015, therapeutic coverage will
be scaled up by 10 percentage points per year (conservative
compared to reported coverage patterns in projects that started
mass treatment between 1995 and 2010), to a maximum of 75%
(conservative compared to the longest-running projects that
reported stable coverage levels around 80% in 2008–2010).
Simulating trends in infection and morbidity
For each unit of analysis (project, onchocerciasis type,
endemicity), we simulated trends in infection, morbidity, and
mortality in the ONCHOSIM model [6–8], considering the
project-specific history of mass treatment (File S1). For each
endemicity stratum, ONCHOSIM was calibrated so that it could
reproduce the average pre-control level of infection (File S1).
Furthermore, ONCHOSIM was calibrated to reproduce the
association between the prevalence of infection and morbidity
(visual impairment, blindness, and itch) as estimated by analysis of
literature data (File S1). Based on previous studies with
ONCHOSIM, we assumed that ivermectin instantly kills all
microfilariae and permanently reduces the capacity of adult female
worms to release microfilariae by 35% in treated individuals (with
Author Summary
In 1995, the World Health Organization launched the
African Programme for Onchocerciasis Control (APOC) with
the aim to control morbidity due to the parasitic infectious
disease onchocerciasis (river blindness). APOC aims to set
up sustainable national control programs against oncho-
cerciasis in 16 countries in sub-Saharan Africa, covering
over 100 million people who are at risk for infection. The
main control strategy is mass treatment with the drug
ivermectin, which is donated by the pharmaceutical
company Merck. Coordination of the mass treatment
programs is made possible by financial contributions from
donor and beneficiary countries. We estimated that
between 1995 and 2010, APOC has had a huge impact
on population health in sub-Saharan Africa, preventing 8.2
million years worth of healthy life from being lost due to
disease and mortality, at a cost of about US$257 million.
We predicted that this health impact will double during
the subsequent five years, at a cost of about US$221
million. This makes APOC one of the most cost-efficient
large-scale public health programs in the world. We may
expect even greater health gains in the future, given the
anticipated extension of the APOC mandate with the aim
to eliminate infection where possible.
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cumulative effects for repeated treatments) [4,7]. Individual
participation in mass treatment was assumed to depend on age,
sex (pregnant women and children under the age of five were
assumed to be excluded from treatment), random non-compliance
(i.e., temporal factors), and systematic non-compliance (i.e., fixed
individual factors other than age and sex e.g. inclination towards
participation). Systematic non-compliance was assumed to play a
larger role when overall treatment coverage was lower (i.e. when
there is lower inclination to participate in general), and vice versa
[6,8]. No simulations were performed for hypoendemic areas, as
ONCHOSIM predicts that transmission of infection is unsustain-
able without migration of infected flies and/or human, and
information on migration was lacking. Instead, we assumed that
the prevalence of infection and morbidity in hypoendemic areas
was 1/3 of that in mesoendemic areas, both pre-control and
during control. For non-endemic areas, we assumed that
prevalence of infection and morbidity was always zero.
Calculating the health impact
We combined the predicted trends in prevalence of infection,
morbidity, and mortality with information on the number of
people at risk, yielding an estimate of the absolute number of cases
of infection, morbidity, and deaths in each stratum. After
aggregation of these results over all APOC projects, we calculated
the burden of disease in terms of disability-adjusted life years
(DALYs), which in our case is the sum of years lived in disability
due to troublesome itch, visual impairment, and blindness,
weighted by the loss of quality of life due to each symptom:
0.068, 0.282, and 0.594, respectively [9]; and years of life lost due
to excess mortality from blindness (File S1). Every incident case of
blindness was attributed 8 years of life lost, based on the average
age of onset of blindness in ONCHOSIM, the associated life-
expectancy (16 years) of a healthy person of the same age, and an
estimated 50% reduction in remaining life-expectancy due to
blindness (File S1). The estimated annual burden of disease was
compared to the burden in a counterfactual scenario in which the
pre-control prevalence of infection and morbidity did not change
(i.e., as if there were no mass treatment), yielding an estimate of the
averted disease burden. All DALY estimates in the present study
are undiscounted.
Sensitivity analysis
We assessed the influence of uncertain model assumptions on
the estimated health impact, by means of univariate and
multivariate sensitivity analyses (File S1). In a univariate sensitivity
analyses, we assumed extreme, though plausible parameter values
for each of the selected parameters. In a multivariate sensitivity
analysis, the analysis was repeated, based on 200 sets of random
parameter values. Parameter values were randomly drawn from
triangular distributions with modes equal to the values used in the
main analysis, and minimum and maximum values equal to those
used in the univariate sensitivity analyses. To arrive at a crude
estimate of the uncertainty in the estimated health impact, the
results of the multivariate sensitivity analysis were expressed as the
2.5 and 97.5 percentiles of results from 200 repeated analyses.
Estimating the cost of APOC
We estimated the financial costs for coordination of ivermectin
mass treatment taken on by APOC and national onchocerciasis
task forces (beneficiary governments and non-governmental
development organizations), based on APOC financial reports
for The World Bank, which acts as fiscal agent for APOC. Because
governments of beneficiary countries will eventually have to
finance and coordinate ivermectin mass treatment, costs were
estimated from a program perspective, not accounting for
community costs and costs of donated drugs. For the years
1995–2003 and 2010, cost data for national onchocerciasis task
forces were not available and were assumed to be proportional to
APOC expenditures by a factor based on data available for other
years. Expenditures for 2011–2015 were estimated based on the
expected number of treatments in that period multiplied by the
estimated cost per treatment in 2010. All costs are reported in
nominal values, by which we mean that the presented costs are the
amounts that were actually spent (i.e. uncorrected for inflation,
and undiscounted).
Results
In 1995, the total population size in the APOC target area was
71.5 million (Figure 1), with 30% of the APOC target population
living in hyperendemic communities, 31% in mesoendemic
communities, 38% in hypoendemic communities surrounded by
mesoendemic or hyperendemic areas, and 1% living in non-
endemic communities. About 30% of the APOC population lived
in savanna areas and 70% in forest or forest–savanna mosaic areas
(Table 1). Before the inception of APOC in 1995, about 32 million
people (45%) in APOC areas were infected with onchocerciasis,
with 404,000 people (0.6%) blind because of onchocerciasis,
another 889,000 (1.2%) suffering from visual impairment, and 10
million people (14%) suffering from troublesome itch. In the same
year, a total of 1.6 million DALYs (22.8 DALYs per 1,000 persons)
were lost due to onchocerciasis: 694,000 because of troublesome
itch, 684,000 from blindness, and 251,000 due to visual
impairment.
Mass treatment effectively started in 1997 (80,000 treatments)
and was scaled up over the years, reaching an overall therapeutic
coverage of about 73% in 2010 (75.8 million treatments; Figure 1).
We estimated that the therapeutic coverage will increase to 78%
by 2015 (92.5 million treatments). By 2010, about 65% of the
population lived in areas subjected to 10–13 rounds of mass
treatment, 17% in areas subjected to 6–9 rounds of mass
treatment, 18% in areas subjected to 3–5 rounds of mass
treatment, and less than 1% in areas subjected to only 1–2 rounds
of mass treatment (Table 1). Cumulatively, about 500 million
treatments with ivermectin were given between 1995 and 2010,
with another 430 million expected to follow in the period 2011–
2015. Considering the differences between projects in start year
and patterns of scaling up of mass treatment, the prevalence of
infection for APOC as a whole declined gradually and non-linearly
over time, from 45% in 1995 to 31% in 2010, and to 18% in 2015
(Figure 2). Similarly, the prevalence of troublesome itch was
reduced from 14% to 6% to 2%, and prevalence of visual
impairment was reduced from 1.2% to 0.8% to 0.6%. Because of
excess mortality among the blind and the fact that ivermectin
prevented blindness in individuals who were already visually
impaired, the prevalence of blindness declined more rapidly than
that of visual impairment: from 0.6% to 0.3% to 0.2%.
In the counterfactual scenario without mass treatment, in which
levels of infection and morbidity were stable, the absolute number
of DALYs lost due to onchocerciasis would have increased over
the years with population growth. In contrast, in the scenario that
considers mass treatment with ivermectin, the absolute number of
DALYs lost was predicted to decrease over the years. Due to these
divergent trends, the number of DALYs averted by mass treatment
with ivermectin was predicted to increase year by year (Figure 3).
Overall, mass treatment with ivermectin averted 8.2 million
DALYs between 1995 and 2010 (3.2 million due to itch, 4.4
million due to blindness, 0.6 million due to visual impairment).
APOC 1995-2015: Health Impact and Cost
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Moreover, we expect that APOC will avert another 9.2 million
DALYs in the period 2011–2015, adding up to an expected total
of 17.4 million averted DALYs by 2015 (Table 2). In relative
terms, the disease burden of onchocerciasis was reduced from 22.8
DALYs per 1,000 persons in 1995 to 9.6 DALYs per 1,000
persons in 2010, and is expected to be further reduced to 5.0
DALYs per 1,000 persons by 2015.
Univariate sensitivity analyses identified the following parameters
as having the most influence on the estimated health impact: the
population at risk, pre-control levels of infection, and the associations
between infection and itch and eye disease (Figure 4). The
multivariate sensitivity analysis showed that the estimated cumulative
number of DALYs averted could be up to 25% higher or lower, when
we considered the separate sources of uncertainty simultaneously
(6.0–9.8 million DALYS cumulatively averted by 2010, and 13.1–
21.3 million DALYs cumulatively averted by 2015; Figure 4).
Between 1995 and 2010, coordination of mass treatment cost
roughly US$257 million (Table 2), of which US$175 million was
disbursed by APOC and US$82 million by national onchocerciasis
task forces (cost of donated drugs and government salaries not
included). Assuming that costs will rise proportionally with the
number of treatments, mass treatment was expected to cost
another US$221 million between 2011 and 2015, adding up to a
total cost of US$478 million by 2015.
Figure 1. Population at risk and treated in areas covered by the African Programme for Onchocerciasis Control. Dots represent time
points for which data were available; projections for 2011–2015 (shaded area) are based on the assumptions that populations continue to grow
according to the latest known growth rates and that all projects scale up therapeutic coverage by 10 percentage points per year (up to a maximum
coverage of 75%).
doi:10.1371/journal.pntd.0002032.g001
Table 1. Size and distribution of population in APOC target areas (thousands and fraction of total).
Number of treatment rounds provided through 2010
Onchocerciasis type Endemicity class 1–2 3–5 6–9 10–13 Total
Forest/mixed Non-endemic 3 0.0% 129 0.1% 119 0.1% 342 0.3% 593 0. 6%
Forest/mixed Hypoendemic 155 0.1% 5,669 5.4% 5,245 5.0% 14,170 13.6% 25,239 24.3%
Forest/mixed Mesoendemic 71 0.1% 4,179 4.0% 4,210 4.0% 11,768 11.3% 20,228 19.4%
Forest/mixed Hyperendemic 13 0.0% 4,128 4.0% 5,428 5.2% 15,201 14.6% 24,770 23.8%
Forest/mixed Total 243 0.2% 14,104 13.6% 15,002 14.4% 41,481 39.9% 70,831 68.1%
Savanna Non-endemic 0 0.0% 1 0.0% 1 0.0% 18 0.0% 19 0.0%
Savanna Hypoendemic 0 0.0% 871 0.8% 1,048 1.0% 12,837 12.3% 14,756 14.2%
Savanna Mesoendemic 0 0.0% 1,695 1.6% 1,143 1.1% 9,402 9.0% 12,240 11.8%
Savanna Hyperendemic 0 0.0% 1,900 1.8% 255 0.2% 4,049 3.9% 6,203 6.0%
Savanna Total 0 0.0% 4,467 4.3% 2,446 2.4% 26,306 25.3% 33,219 31.9%
Grand Total 243 0.2% 18,571 17.8% 17,449 16.8% 67,787 65.1% 104,050 100.0%
Populations were stratified by onchocerciasis type, endemicity class and the history of mass treatment. The history of mass treatment is expressed as the number of
treatment rounds provided through 2010.
doi:10.1371/journal.pntd.0002032.t001
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Discussion
We estimated the health impact and cost of mass treatment with
ivermectin for the 20-year period that APOC is scheduled to run
as a morbidity control program (1995–2015). Our simulations
suggest that mass treatment with ivermectin has markedly reduced
the prevalence of infection with O. volvulus, troublesome itch, visual
impairment, and blindness in APOC areas, averting an estimated
8.2 million DALYs due to onchocerciasis by 2010 at a nominal
financial cost of about US$257 million (excluding cost of donated
drugs). We expect that APOC will avert another 9.2 million
DALYs between 2011 and 2015, at a nominal financial cost of
US$221 million.
Our estimate of APOC’s health impact only considered eye
disease and troublesome itch, and would be even higher if other
clinical manifestations of onchocerciasis would have been taken
into account. For instance, disfiguring skin disease also contrib-
utes to the disease burden of onchocerciasis and is known to be
reduced by ivermectin [10–13]. Further, epilepsy may be
associated with onchocerciasis, as suggested by a growing but
still uncertain base of evidence [14]. However, we chose to
include only the most important disease manifestations for which
data were available for model calibration (i.e., eye disease and
troublesome itch). Furthermore, we did not include the effect of
ivermectin on diseases that are co-endemic with onchocerciasis,
such as soil transmitted helminthiases, ectoparasitic infections,
and lymphatic filariasis [15]. Other minor factors leading to an
underestimation of the health impact are that we only considered
the effect of ivermectin on the capacity of adult female worms to
release microfilariae and its microfilaricidal effect, whereas
ivermectin may additionally have a modest effect on adult worm
viability [16,17]. Furthermore, we ignored between-village
variation in coverage, which is perhaps most extreme in the
phase of scaling up: in some projects, treatment started in a
Figure 2. Predicted prevalence of onchocercal infection and morbidity in APOC areas from 1995 to 2015. Please note the different
scales for the y-axes in the four panels. Shaded areas represent projections for 2011–2015. A) Prevalence of infection is defined as infestation with at
least one adult female worm, or alternatively, presence of detectable microfilariae in the skin. B) Prevalence of troublesome itch, caused by
onchocerciasis. C) Prevalence of onchocercal visual impairment, defined as corrected visual acuity (i.e. measured with glasses on or through pinhole)
of ,18/60 and $3/60 in the better eye. D) Prevalence of onchocercal blindness, defined as corrected visual acuity (i.e. measured with glasses on or
through pinhole) of ,3/60 or restriction of visual field to less than 10u in the better eye.
doi:10.1371/journal.pntd.0002032.g002
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subpopulation with high coverage, while the other part of the
population did not yet receive mass treatment (which is more
efficient than treating the entire project population at an
equivalent average coverage). We may have somewhat overesti-
mated the number of life years lost due to excess mortality from
blindness during and after mass treatment, causing a small
underestimation in the number of DALYs averted. This is
because we appointed a fixed number of life years lost to every
new case of blindness, while regular ivermectin treatment is
expected to postpone the onset of blindness to a higher age,
reducing the number of life years lost due to blindness.
Furthermore, we did not consider a possible association between
excess mortality and (high) microfilarial load [18,19].
There are several factors that may (partly) counterweigh the
underestimation of the health impact of APOC described above.
Therapeutic coverage may have been over-reported by commu-
nity members responsible for the distribution of ivermectin, either
because of incomplete estimates of the community population or
to inflate their own performance. Yet, the estimated health impact
of APOC by 2015 would decrease by only 0.8 million averted
DALYs if we assume that coverage were to be systematically 10%
lower than reported. Also, we ignored any mass treatment prior to
the inception of APOC, whereas in reality, ivermectin distribution
had already started in a limited number of foci (here morbidity
levels had already been reduced somewhat, but not on account of
APOC). Taking all above sources of under- and over-estimation
into account, we believe that the true health impact of APOC is
still slightly higher than our calculations.
The validity of our results, as in any simulation study, depends
on the quality of the model and its assumptions. ONCHOSIM was
first developed in the early nineties and has earned trust over the
years from the large scale control programs. ONCHOSIM has
been used to successfully mimic observed epidemiological data
from various locations [4,20–22], and has been used for policy
making in the West-African Onchocerciasis Control Programme
[7]. Efforts to validate the model continue. We have recently
compared ONCHOSIM predictions to longitudinal data from
Senegal and Gambia [23] and found that model-predicted trends
in mf prevalence during 14 to 16 years of mass treatment were
broadly consistent with the observed trends, although the mf
prevalence sometimes seemed to decline slightly faster than
predicted (unpublished data). Furthermore, our model predictions
for trends in itch were comparable to the reported average trend in
APOC sentinel areas [13]; after five to six years of mass treatment
at 70–80% coverage, itch prevalence was reported to decline from
16% to 7%, and we predicted a decline from 14% to 6.5% for
areas with similar pre-control levels of infection and history of
mass treatment. Likewise, our model adequately reproduced
trends in onchocercal blindness during vector control in West
Africa (File S1). Although the above suggests that our model
predictions are realistic, our estimates remain subject to uncer-
tainty and it would be good to have them confirmed by more field
data, especially regarding trends in morbidity during mass
treatment.
Even though the model seems to be reliable, we should consider
potentially important sources of uncertainty in our analysis. An
Figure 3. Disability-adjusted life years (DALYs) lost due to onchocerciasis from 1995 to 2015. The total height of the bars (colored plus
blank) represents the estimated number of DALYs lost in a counterfactual scenario without ivermectin mass treatment (increasing trend due to
population growth). The colored part of each bar represents the estimated actual number of DALYs lost (declining trend due to ivermectin mass
treatment). The blank part of each bar therefore represents the annual number of DALYs averted by ivermectin mass treatment in the total APOC
population.
doi:10.1371/journal.pntd.0002032.g003
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often debated factor concerns the effect of ivermectin on adult
worms. The univariate sensitivity analysis showed that the
assumed treatment effects of ivermectin on the capacity of adult
worms to release microfilariae influenced the estimated health
impact only marginally. We did not study the effects of assuming
no cumulative effects of ivermectin on worm fecundity, whereas it
has been suggested that the latter may be the case [24]. However,
if we had, ivermectin efficacy parameters would have been
calibrated such that the model-predicted trends in mf prevalence
and density were still in agreement with observed trends [4,22],
and therefore predicted trends in infection levels and morbidity
should not have differed much from the current model’s
predictions. The sensitivity analysis showed that alternative
assumptions for the effect of ivermectin on itch (the only reversible
symptom under consideration) also influenced the estimated health
impact only marginally. The most influential assumptions in our
analysis were related to the estimated size of the population at risk,
pre-control levels of infection, and the assumed associations
between infection and morbidity, which were all based on data.
Even though the multivariate sensitivity analysis suggested
considerable overall uncertainty in our estimate of the health
impact (625%), the magnitude of the predicted impact was always
large.
With an estimated 8.2 million DALYs averted in a 15-year
period and a predicted doubling in the subsequent 5 years, the
predicted health impact of APOC is impressive. According to our
calculations, mass treatment against onchocerciasis cost about a
nominal US$31 per undiscounted DALY averted between 1995
and 2010. According to World Health Organization guidelines
[25], this is highly cost-effective, as it is below the per capita gross
domestic product of most countries covered by APOC (27–1,545
international dollar per capita; Global Health Observatory Data
Repository, accessed 2 August 2012). Furthermore, this cost-
effectiveness is comparable to or even better than those for several
other public health interventions. For example, the life-time cost-
effectiveness of prophylaxis against mother-to-child transmission of
HIV in a resource-limited setting has been estimated at US$52 per
undiscounted DALY (incremental cost-effectiveness ratio of World
Health Organization guidelines versus minimal standard of care)
[26]. The cost-effectiveness of large-scale, long-term (30-year
period) public health interventions targeting other neglected
tropical diseases has been estimated at US$4–US$29 per DALY
Table 2. Health impact and cost of ivermectin mass treatment, 1995–2015.
Year
Health impact in number of DALYs




1995 0.00 0.0 0.0 0.0
1996 0.00 2.4 1.1 3.6
1997 0.00 2.4 1.1 3.6
1998 0.03 9.3 4.4 13.7
1999 0.13 9.3 4.4 13.7
2000 0.21 9.2 4.3 13.5
2001 0.29 9.2 4.3 13.5
2002 0.39 9.1 4.3 13.3
2003 0.47 11.3 5.3 16.7
2004 0.58 12.6 5.1 17.8
2005 0.69 13.5 4.0 17.6
2006 0.79 11.0 6.0 17.0
2007 0.92 13.7 7.7 21.4
2008 1.05 13.7 7.5 21.3
2009 1.23 21.2 10.0 31.1






Subtotal 1995–2010 8.20 174.8 82.1 256.9
Total 1995–2015 17.39 478.1
The health impact is expressed as the annual number of DALYs averted. Costs include those taken on by the African Programme for Onchocerciasis Control (APOC) and
national onchocerciasis task forces (including beneficiary governments and non-governmental development organizations). All costs are expressed in nominal US$ (i.e.,
uncorrected for inflation and undiscounted), and do not include cost of donated drugs or government salaries.
*National onchocerciasis task force expenditures for the years 1995–2003 and 2010 were unknown; they were assumed to be equal to 47% of APOC expenditures, based
on known expenditures for the years 2004–2009.
**Expenditures for 2011–2015 were estimated based on the expected number of treatments in that period multiplied by the estimated cost per treatment in 2010
($0.52).
doi:10.1371/journal.pntd.0002032.t002
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(mass drug administration against lymphatic filariasis), US$38 per
DALY (case detection and treatment for leprosy), US$260 per
DALY (vector control against Chagas disease), and US$48–
US$303 (vector control against lymphatic filariasis) [27]. Mass
treatment against onchocerciasis is of even better value (US$27 per
DALY) if expected health gains and costs for the period 2011–
2015 are included. In view of the anticipated elimination of
infection so that mass treatment can be stopped altogether, the
cost-effectiveness will be even better than our calculations suggest
[23].
The objective of APOC is to establish country-led systems for
onchocerciasis control by 2015, which means that countries and
their partners will have to carry full financial responsibility by that
year. Our results indicate that cost per treatment with ivermectin
in APOC areas is affordable (US$0.51 per treatment, excluding
cost of donated drugs) and comparable to the costs of existing
national mass treatment programs for the elimination of lymphatic
filariasis (US$0.06–US$2.23 per treatment) [28]. Mass treatment
with ivermectin, however, also involves costs for society not
covered by the program. From published data for two Nigerian
communities, we derived that these costs are about US$0.23 per
treatment (excluding start-up costs) [29]. Based on this estimate,
the sum of program and community costs for mass treatment with
ivermectin was approximately US$370 million from 1995 to 2010
and will be another US$320 million for 2011–2015. In addition to
costs, there are significant benefits for society that countries need
to take into account, such as prevented productivity losses resulting
from blindness and itch. Blindness in rural Africa has previously
been assumed to result in an annual productivity loss of US$150
per case [30]. Likewise, the productivity loss due to itch among
coffee plantation workers in an Ethiopian site has been estimated
at around US$5.32 per month per case [12]. Combined with our
predictions of health impact, these figures suggest that by 2015,
APOC will have averted a staggering US$2.2 billion due to
productivity losses from blindness (US$517 million) and itch
(US$1.7 billion, assuming productivity losses in 25% of people
with itch). In other words, beneficiary countries should expect
economic benefit from mass treatment that outweighs any costs.
Clearly, all of the above calculations apply only under the
condition that countries do not themselves pay for the drug
ivermectin. The amount of ivermectin donated up to 2010
represents a value of US$2.1 billion, assuming 2.8 tablets per
treatment and a commercial price per tablet of US$1.50 plus
US$0.005 shipping costs (personal communication with Dr. A.
Hopkins, director of the Mectizan Donation Program). This
amount is eight times the program costs for coordinating mass
treatment. Likewise, for the period 2011–2015, the value of
donated ivermectin will be an additional US$1.8 billion. There-
fore, mass treatment with ivermectin can be sustained only with
donation of ivermectin, which Merck has pledged to continue for
as long as necessary.
We expect that levels of infection in the APOC target area will
have fallen drastically by 2015 (overall prevalence of adult female
worms 18%). The implication is that by that time, transmission of
infection may be almost interrupted in areas with favorable
conditions for elimination, such as high coverage of mass
treatment, sufficient treatment rounds, and/or low to medium
pre-control levels of infection [31]. Until recently, elimination of
onchocerciasis from Africa was thought to be impossible by means
of mass treatment alone, considering the large size of the
transmission zones, mobility of the vectors and human popula-
tions, and poor compliance with mass treatment [32]. Following
reports of elimination of onchocerciasis from foci in Mali and
Senegal by mass treatment alone [23], however, interest has
Figure 4. Sensitivity analysis for the estimated cumulative number of DALYs averted by 2015. The multivariate sensitivity analysis (last
item) consisted of 200 repeated analyses, based on 200 sets of random parameter values, which were drawn from triangular distributions with modes
equal to parameter values used in the main analysis, and minimum and maximum values equal to parameter values used in the univariate sensitivity
analysis (first eight items of this figure). The results of the multivariate sensitivity analysis are expressed as the 2.5 and 97.5 percentiles of results from
200 repeated analyses.
doi:10.1371/journal.pntd.0002032.g004
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renewed in elimination of onchocerciasis from Africa [33].
Following this, WHO has recently been advised to extend APOC
mandate by ten years to 2025 with the new aim of eliminating
infection with O. volvulus, where possible. With this new
motivation, we may indeed expect focal elimination of infection,
resulting in even more health gains from mass treatment with
ivermectin in the future and the possibility of being able to end
mass treatment altogether.
According to our simulations, APOC has had a remarkable
impact on population health in Africa between 1995 and 2010.
This health impact is expected to double during the subsequent
five years. Further, APOC is a highly cost-effective public health
programs, and given the anticipated elimination of onchocerciasis
from APOC areas, we expect even more health gains and a more
profitable cost-effectiveness of mass treatment with ivermectin in
the near future. Our study fully supports the advice to continue
APOC activities for another ten years.
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